{"id":"NCT03185013","sponsor":"Inovio Pharmaceuticals","briefTitle":"REVEAL 1 (Evaluation of VGX-3100 and Electroporation for the Treatment of Cervical HSIL)","officialTitle":"A Prospective, Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of VGX-3100 Delivered Intramuscularly Followed by Electroporation With CELLECTRA™-5PSP for the Treatment of HPV-16 and/or HPV-18 Related High Grade Squamous Intraepithelial Lesion (HSIL) of the Cervix","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2017-06-28","primaryCompletion":"2020-07-08","completion":"2021-04-06","firstPosted":"2017-06-14","resultsPosted":"2023-07-25","lastUpdate":"2023-07-27"},"enrollment":201,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Cervical Dysplasia","Cervical High Grade Squamous Intraepithelial Lesion","HSIL"],"interventions":[{"type":"BIOLOGICAL","name":"VGX-3100","otherNames":[]},{"type":"BIOLOGICAL","name":"Placebo","otherNames":[]},{"type":"DEVICE","name":"Electroporation (EP)","otherNames":[]}],"arms":[{"label":"VGX-3100 + EP","type":"EXPERIMENTAL"},{"label":"Placebo + EP","type":"PLACEBO_COMPARATOR"}],"summary":"HPV-301 is a prospective, randomized, double-blind, placebo controlled Phase 3 study to determine the efficacy, safety, and tolerability of VGX-3100 administered by intramuscular (IM) injection followed by electroporation (EP) delivered with CELLECTRA™ 5PSP in adult women with histologically confirmed cervical high grade squamous intraepithelial lesion (HSIL) (cervical intraepithelial neoplasia grade 2 \\[CIN2\\] or grade 3 \\[CIN3\\]) associated with human papillomavirus (HPV) 16 and/or HPV-18.","primaryOutcome":{"measure":"Percentage of Participants With No Evidence of Cervical HSIL on Histology and No Evidence of HPV-16 and/or HPV-18 in Cervical Samples","timeFrame":"Week 36","effectByArm":[{"arm":"VGX-3100 + Electroporation (EP)","deltaMin":22.5,"sd":null},{"arm":"Placebo + EP","deltaMin":11.1,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.029"}]},"eligibility":{"minAge":"18 Years","sex":"FEMALE","healthyVolunteers":false,"inclusionCount":7,"exclusionCount":13},"locations":{"siteCount":60,"countries":["United States","Argentina","Belgium","Estonia","Finland","Germany","Italy","Lithuania","Mexico","Peru","Philippines","Poland","Portugal","Puerto Rico","Slovakia","South Africa","Spain","Thailand","United Kingdom"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":13,"n":136},"commonTop":["Injection Site Pain","Headache","Fatigue","Injection Site Pruritus","Injection Site Erythema"]}}